alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 522.883 Etorphine. ( a ) *Specifications.* Each milliliter of solution contains 1 milligram of etorphine hydrochloride.
( b ) *Sponsor.* See No. 053923 in § 510.600(c) of this chapter.
( c ) *Special considerations.* Distribution is restricted to veterinarians engaged in zoo and exotic animal practice, wildlife management programs, and researchers.
( d ) *Conditions of use* — ( 1 ) *Amount.* Administered intramuscularly by hand syringe or syringe dart at a suitable dosage level depending upon the species.
( 2 ) *Indications for use.* For the immobilization of wild and exotic animals.
( 3 ) *Limitations.* Do not use in domestic food-producing animals. Do not use 30 days before, or during, the hunting season in free-ranging wild animals that might be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16188, Mar. 25, 2014]
iddr_ex103.htm

EXHIBIT 10.3

 

AMENDMENT #1 TO THE SECURITIES PURCHASE AGREEMENT AND CONVERTIBLE PROMISSORY NOTE DATED APRIL 10, 2017 

 

THIS AMENDMENT #1 (the “Amendment”) TO THE SECURITIES PURCHASE AGREEMENT AND CONVERTIBLE PROMISSORY NOTE dated April 10, 2017, is made effective as of April 10, 2017, by and between IDDriven, Inc., a Nevada corporation (the “Company”), and Crown Bridge Partners, LLC, a New York limited liability company (the “Holder”) (collectively the “Parties”).

 

BACKGROUND

 

A. The Company and Holder are the parties to that certain securities purchase agreement (the “SPA”) and convertible promissory note (the “Note”) in the principal amount of $55,000.00, dated April 10, 2017; and

 

B. The Parties desire to amend the Note and SPA as set forth expressly below, to correct a scrivener’s error in the Note and SPA and reflect the Parties’ intentions at the time of execution. 

 

NOW THEREFORE, in consideration of the execution and delivery of the Amendment and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

1. All references tin the Note and SPA to 3% and three percent, with respect to the current interest rate of the Note, shall be replaced with 1% and one percent, respectively.

 

2. This Amendment shall be deemed part of, but shall take precedence over and supersede any provisions to the contrary contained in the SPA. Except as specifically modified hereby, all of the provisions of the SPA, which are not in conflict with the terms of this Amendment, shall remain in full force and effect.

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 


	
IDDriven, Inc.
	
 
	
Crown Bridge Partners, LLC
	
 

	
 
	 	 	 	 	 
	
By:
	/s/Arend D. Verweij	 	By:	/s/	 
	
Name:
	Arend D. Verweij	 	Name:	 	 
	
Title:
	Chief Executive Officer	 	Title:
EX-31

          RULE 13a-14(a)/15d-14(a) CERTIFICATION OF EDWARD H. WEBB

                     RULE 13a-14(a)/15d-14(a) CERTIFICATION

I, Edward H. Webb, President, certify that:

1.  I have reviewed this quarterly report on Form 10-QSB of W-J
International, Ltd.;

2.  Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to
the period covered by this report;

3.  Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the small business issuer as of, and for, the periods
presented in this report;

4.  I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) [omitted pursuant to extended compliance period] for
the small business issuer and have:

(a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under my
supervision, to ensure that material information relating to the
small business issuer, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly
during the period in which this report is being prepared;

(b)  [omitted pursuant to extended compliance period]

(c) Evaluated the effectiveness of the small business issuer's
disclosure controls and procedures and presented in this report
my conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this
report based on such evaluation; and

(d) Disclosed in this report any change in the small business
issuer's internal control over financial reporting that occurred
during the small business issuer's most recent fiscal quarter
(the small business issuer's fourth fiscal quarter in the case of
an annual report) that has materially affected, or is reasonably
likely to materially affect, the small business issuer's internal
control over financial reporting; and

5.  I have disclosed, based on my most recent evaluation of internal
control over financial reporting, to the small business issuer's
auditors and the audit committee of the small business issuer's board
of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the small
business issuer's ability to record, process, summarize and
report financial information; and

(b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the small
business issuer's internal control over financial reporting.


Dated: August 12, 2004                 By: /s/  Edward H. Webb
                                       Edward H. Webb, President
|   | 1. | I have reviewed this Quarterly Report on Form 10-Q/A of Crimson Exploration Inc.; |
|--------|----|-----------------------------------------------------------------------------------|

|   | 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:  | August 30, 2010         |   |
|-------------|-------------------------|--------|
|        | /s/ E. Joseph Grady     |   |
| Name:       | E. Joseph Grady         |   |
| Title:      | Senior Vice President   |   |
|        | Chief Financial Officer |   |
Exhibit 32.1



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Annual Report of Ambassadors International, Inc. (the Company) on Form 10-K for the year ended December 31, 2004 as filed with the
Securities and Exchange Commission on the date hereof (the Report), the undersigned, Joseph J. Ueberroth, Chief Executive Officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                                                                                    
|------------------------------------------------------------------------------------
|                                                                                    
|/s/    JOSEPH J.
UEBERROTHJoseph J.
Ueberroth Chief Executive Officer March 16, 2005
|
|
|



The foregoing
certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. §1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into
any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
The Schedule contains summary financial information extracted from the condensed
consolidated balance sheet of Dictaphone Corporation at December 31, 1999
and the condensed consolidated statement of operations for the 12 months ended
December 31, 1999 and is qualified in its entirety by reference to such
financial statements.
</LEGEND>
<CIK>                         0000946734
<NAME>                        Dictaphone Corporation
<MULTIPLIER>                                   1
<CURRENCY>                                     US dollars

<S>                             <C>
<PERIOD-TYPE>                   12-Mos
<FISCAL-YEAR-END>                              Dec-31-1999
<PERIOD-START>                                 Jan-01-1999
<PERIOD-END>                                   Dec-31-1999
<EXCHANGE-RATE>                                          1
<CASH>                                               6,190
<SECURITIES>                                             0
<RECEIVABLES>                                      102,635
<ALLOWANCES>                                         1,801
<INVENTORY>                                         49,759
<CURRENT-ASSETS>                                   162,935
<PP&E>                                              77,884
<DEPRECIATION>                                      40,395
<TOTAL-ASSETS>                                     461,138
<CURRENT-LIABILITIES>                              102,538
<BONDS>                                            353,443
<PREFERRED-MANDATORY>                               49,730
<PREFERRED>                                              0
<COMMON>                                               130
<OTHER-SE>                                        (67,462)
<TOTAL-LIABILITY-AND-EQUITY>                       461,138
<SALES>                                            258,061
<TOTAL-REVENUES>                                   353,734
<CGS>                                              189,195
<TOTAL-COSTS>                                      321,633
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                  40,062
<INCOME-PRETAX>                                    (7,906)
<INCOME-TAX>                                       (1,037)
<INCOME-CONTINUING>                                (8,943)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                       (8,943)
<EPS-BASIC>                                              0
<EPS-DILUTED>                                            0




</TABLE>
##### 



Exhibit 99.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Capital Pacific Holdings, Inc. (the
Company) on Form 10-Q for the period ending November 30, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the Report), I, Steven
O. Spelman, Jr., Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. § 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) |  | The Report fully complies with the requirements of section
13(a) or 15(d) of the Securities Exchange Act of 1934; and                              
| | --- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------
|
| | (2) |  | The information contained in the Report fairly presents, in all
material respects, the financial condition and result of
operations of the Company.

| |                                                                                                     |                               
| | --------------------------------------------------------------------------------------------------- | ------------------------------
| | By:                                                                                                 | /s/     Steven O. Spelman, Jr.
| |                                                                                                    
| | Steven O. Spelman, Jr.Chief Financial Officer and Corporate Secretary
(Principal Financial Officer)

Date: January 14, 2003
§ 701.2 Form of stating labeling requirements. ( a ) A word, statement, or other information required by or under authority of the Act to appear on the label may lack that prominence and conspicuousness required by section 602(c) of the Act by reason (among other reasons) of: ( 1 ) The failure of such word, statement, or information to appear on the part or panel of the label which is presented or displayed under customary conditions of purchase;
( 2 ) The failure of such word, statement, or information to appear on two or more parts or panels of the label, each of which has sufficient space therefor, and each of which is so designed as to render it likely to be, under customary conditions of purchase, the part or panel displayed;
( 3 ) The failure of the label to extend over the area of the container or package available for such extension, so as to provide sufficient label space for the prominent placing of such word, statement, or information;
( 4 ) Insufficiency of label space (for the prominent placing of such word, statement, or information) resulting from the use of label space for any word, statement, design, or device which is not required by or under authority of the Act to appear on the label;
( 5 ) Insufficiency of label space (for the prominent placing of such word, statement, or information) resulting from the use of label space to give materially greater conspicuousness to any other word, statement, or information, or to any design or device;
( 6 ) Smallness or style of type in which such word, statement, or information appears, insufficient background contrast, obscuring designs or vignettes, or crowding with other written, printed, or graphic matter.
( b ) ( 1 ) All words, statements, and other information required by or under authority of the Act to appear on the label or labeling shall appear thereon in the English language: *Provided, however,* That in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant language is one other than English, the predominant language may be substituted for English.
( 2 ) If the label contains any representation in a foreign language, all words, statements, and other information required by or under authority of the Act to appear on the label shall appear thereon in the foreign language.
( 3 ) If the labeling contains any representation in a foreign language, all words, statements, and other information required by or under authority of the Act to appear on the label or labeling shall appear on the labeling in the foreign language.
February 10, 2015

U. S. Department of Transportation 

Docket Management System

1200 New Jersey Ave., SE 

Washington, DC 20590

Dear Sir or Madam:

Attached please find Skycatch, Inc.’s request for an exemption from the listed Federal 

Aviation Regulations to allow commercial operation of its Small Unmanned Aircraft 

Systems (“sUASs”) for aerial imaging for safety and monitoring of secured and 

controlled environment construction sites. This exemption request is exclusively for the 

use of the UAS manufactured by Skycatch, Inc., a San Francisco based company. 

Also attached to this letter is the Skycatch UAS Flight Manual, which outlines the 

operating requirements, limitations, and technical specifications for the Skycatch system. 

Skycatch submits this manual as a Confidential document under 14 CFR 11.35 (b) as the 

entire manual contains proprietary information that the applicant has not and will not 

share with others. The Manual contains operating conditions and procedures that are not 

available to the public and are protected from release under the Freedom of Information 

Act 5 USC 552 et. seq.

Thank you for your time and consideration, and please let me know if you have any 

questions. 

Sincerely,

Gabriel Dobbs

Director of Policy

Skycatch, Inc.
§ 54.1 Purpose. ( a ) The Food and Drug Administration (FDA) evaluates clinical studies submitted in marketing applications, required by law, for new human drugs and biological products and marketing applications and reclassification petitions for medical devices.
( b ) The agency reviews data generated in these clinical studies to determine whether the applications are approvable under the statutory requirements. FDA may consider clinical studies inadequate and the data inadequate if, among other things, appropriate steps have not been taken in the design, conduct, reporting, and analysis of the studies to minimize bias. One potential source of bias in clinical studies is a financial interest of the clinical investigator in the outcome of the study because of the way payment is arranged (e.g., a royalty) or because the investigator has a proprietary interest in the product (e.g., a patent) or because the investigator has an equity interest in the sponsor of the covered study. This section and conforming regulations require an applicant whose submission relies in part on clinical data to disclose certain financial arrangements between sponsor(s) of the covered studies and the clinical investigators and certain interests of the clinical investigators in the product under study or in the sponsor of the covered studies. FDA will use this information, in conjunction with information about the design and purpose of the study, as well as information obtained through on-site inspections, in the agency's assessment of the reliability of the data.
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 03-7225

PETE SUMNER, Petitioner - Appellant, versus RON ANGELONE, Director, Respondent - Appellee. Appeal from the United States District Court for the Eastern District of Virginia, at Richmond. James R. Spencer, District Judge. (CA-02-220) Submitted: October 9, 2003 Decided: October 21, 2003 Before LUTTIG, KING, and DUNCAN, Circuit Judges. Dismissed by unpublished per curiam opinion. Pete Sumner, Appellant Pro Se. Donald Eldridge Jeffrey, III, OFFICE OF THE ATTORNEY GENERAL OF VIRGINIA, Richmond, Virginia, for Appellee. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: Pete Sumner, a state prisoner, seeks to appeal the district court’s order denying relief on his petition filed under 28 U.S.C. § 2254 (2000). An appeal may not be taken from the final order in a § 2254 proceeding unless a circuit justice or judge issues a certificate of appealability. 28 U.S.C. § 2253(c)(1) (2000). A certificate of appealability will not issue for claims addressed by a district court absent “a substantial showing of the denial of a constitutional right.” 28 U.S.C. § 2253(c)(2) (2000). A prisoner satisfies this standard by demonstrating that reasonable jurists would find both that his constitutional claims are debatable and that any dispositive procedural rulings by the district court are also debatable or wrong. See Miller-El v. Cockrell , 537 U.S. 322, , 123 S. Ct. 1029, 1039-40 (2003); Slack v. McDaniel , 529 U.S. 473, 484 (2000); Rose v. Lee , 252 F.3d 676, 683 (4th Cir.), cert. denied , 534 U.S. 941 (2001). We have independently reviewed the record and conclude that Sumner has not made the requisite showing. Accordingly, we deny a certificate of appealability and dismiss the appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

DISMISSED